Personalis, Inc. provides genomic solutions to support the development of personalized cancer vaccines and other nextgeneration cancer immunotherapies. Our patented ACE Technology improves every step in the sequencing process, from nucleic acid extraction, to sequencing, to data analytics. This delivers augmented coverage of difficult-to-sequence genomic regions that are missed with conventional sequencing techniques. This comprehensive approach provides data of the highest quality to enable the rational design and development of effective cancer immunotherapies.
Find out more: www.personalis.com